Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | MicrobiomeTrials

← Back to trials

NCT07285213

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-12-10Est. Completion: 2027-04-20

Enrollment target: 230 participants

Locations

Research Site, Phoenix, Arizona, United States
Research Site, Chula Vista, California, United States
Research Site, Sacramento, California, United States
Research Site, Torrance, California, United States
Research Site, Hamden, Connecticut, United States
Research Site, Gainesville, Florida, United States
Research Site, Hialeah, Florida, United States
Research Site, Homestead, Florida, United States
Research Site, Jacksonville, Florida, United States
Research Site, Miami Lakes, Florida, United States
Research Site, Miramar, Florida, United States
Research Site, Port Orange, Florida, United States
Research Site, Tamarac, Florida, United States
Research Site, Tampa, Florida, United States
Research Site, Athens, Georgia, United States
Research Site, Atlanta, Georgia, United States
Research Site, Idaho Falls, Idaho, United States
Research Site, Burr Ridge, Illinois, United States

Other microbiome trials you might be interested in

Prophylactic Antibiotic Treatment in HemodialysisRecruiting

Hemodialysis

The purpose of this study is to assess the efficacy of prophylactic antibiotic treatment on blood stream infections and …

Copenhagen, DenmarkEst. completion Oct 2028

High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in OncologyCompleted

Leukemia, Lymphocytic, AcuteLeukemia, Myeloid, AcuteLymphomaClostridium Difficile InfectionSolid Cancers

The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduc…

Aurora, United StatesCompleted Jul 2, 2025

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.